Patents by Inventor Thea Kalebic

Thea Kalebic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
    Patent number: 8697702
    Abstract: The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Phi+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: April 15, 2014
    Assignees: Novartis AG, Medvet Science Pty Ltd
    Inventors: Yanfeng Wang, Thea Kalebic, Timothy P Hughes, Deborah White
  • METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS
    Publication number: 20110312968
    Abstract: The present invention relates to a method tor evaluating patterns to help-optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. Specifically, present invention relates to SHP1 and/or SHP2 as a biomarker for CML patients.
    Type: Application
    Filed: November 5, 2009
    Publication date: December 22, 2011
    Inventors: Nicola Esposito, Barbara Izzo, Thea Kalebic, Fabrizio Pane, Fabrizio Quarantelli
  • Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
    Publication number: 20110224224
    Abstract: The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g.
    Type: Application
    Filed: November 30, 2009
    Publication date: September 15, 2011
    Inventors: Yanfeng Wang, Thea Kalebic, Timothy Peter Hughes, Deborah White
  • Molecular Markers Associated with Bone Metastasis
    Publication number: 20080219996
    Abstract: This invention relates generally to the modulation of expression levels of bone sialoprotein (BSP) in tumors, especially a non-small cell lung cancer tumor, as an indicator of progression to bone metastasis.
    Type: Application
    Filed: September 25, 2006
    Publication date: September 11, 2008
    Inventors: Thea Kalebic, Mauro Giulio Papotti, Giorgio Vittorio Scagliotti
  • Suppression of HIV expression by organic thiophosphate
    Patent number: 5824664
    Abstract: Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: October 20, 1998
    Assignees: U.S. Bioscience, Inc., National Institutes of Health, The National Cancer Institute
    Inventors: Philip S. Schein, Thea Kalebic